跳至主要内容
临床试验/NCT04493827
NCT04493827已完成不适用

Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center

Central Hospital, Nancy, France1 个研究点 分布在 1 个国家目标入组 114 人开始时间: 2011年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
114
试验地点
1
主要终点
Overall survival

研究概览

简要总结

The recent discovery of oncogenic drivers has revolutionized the management of advanced lung cancer by development of tyrosine kinase inhibitors targeted therapies. Prevalence of daily tobacco use is evaluated at 31,3 % in Grand-Est region, the only French region with a statistically significative difference for smoking habits. This region shows a higher incidence (+ 13 %) and mortality for lung cancer in comparison to the average for other French regions. The objectives of our studie were to estimate the distribution of oncogenic drivers and analyse their prognostic impacts in the Nancy University Hospital Center metastatic lung adenocarcinoma's population.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Lung adenocarcinoma
  • Patients diagnosed at a metastatic stage
  • Patient who benefited an oncogenic driver research on their histologic samples
  • Medical follow-up entirely done in Nancy Central Hospital

排除标准

  • Patients with double histology
  • Synchronous cancer
  • Patients with surgical care

结局指标

主要结局

Overall survival

时间窗: over a period of 5 years (Day 0 = anatomopathological diagnosis)

Time (in months) from anatomopathological diagnosis to death

Progression Free survival

时间窗: over a period of 5 years (Day 0 = anatomopathological diagnosis)

Time (in months) from anatomopathological diagnosis to progression of the disease assessed by RECIST criteria

Distribution in percentage of main oncogenic drivers in histological samples from metastatic lung adenocarcinoma

时间窗: At base line (Day 0 = anatomopathological diagnosis)

Distribution in percentage of main oncogenic drivers (KRAS, EGFR, ALK, ROS-1, BRAS and HER2), assessed by Sanger sequencing or FISH method in histological samples from metastatic lung adenocarcinomas

次要结局

  • Distribution in percentage of metastasis sites according oncogenic drivers(At baseline (Day 0 = anatomopathological diagnosis))

研究者

发起方
Central Hospital, Nancy, France
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验